Golimumab after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: four-year retention rate in the Spanish BIOBADASER registry
14/08/2023
M. Pombo-Suarez1 , D. Seoane-Mato2 , F. Diaz-Gonzalez3 , F. Sánchez-Alonso2 , L. Cea-Calvo4 , M. Sánchez-Jareño4 , V. Jovani5 , P. Pretel6 , F. J. Manero Ruiz7 , I. Castrejon8 on behalf of BIOBADASER Investigators
EULAR 2022
DOI: 10.1136/annrheumdis-2022-eular.1560
https://ard.bmj.com/content/81/Suppl_1/1504.2